Table 5.
PVN resolution
| Clinical Parameters | PVN | P Valuea | ||
|---|---|---|---|---|
| Class 1 | Class 2 | Class 3 | ||
| All subjects | ||||
| PVN resolutionb | ||||
| N (%) | 27/36 (75) | 74/95 (78) | 9/18 (50) | 0.17 |
| Time to PVN resolution, wk | ||||
| Median | 12 | 24 | 14 | 0.26 |
| IQRc | 8–42 | 12–44 | 12–32.5 | |
| N | 26 | 70 | 8 | |
| Subjects with negative plasma PCR readings during follow-up | ||||
| PVN resolutiond | ||||
| N (%) | 20/29 (69) | 54/73 (74) | 5/14 (36) | 0.15 |
| Time to clearance, wk | ||||
| Median | 12 | 24 | 48 | 0.23 |
| IQRc | 12–48 | 12–48 | 12–48 | |
| N | 20 | 54 | 5 | |
a
P values for resolution were on the basis of the Cochran–Mantel–Haenszel chi-squared test for nonzero Spearman correlation using the midrank scores. P values for time to PVN resolution and clearance were on the basis of the Kruskal–Wallis test (one-way ANOVA of the rank scores).
b
PVN resolution for all subjects was on the basis of the earliest occurrence of either negative repeat biopsy or negative BK viremia by PCR during follow-up; data are available from n=149 subjects.
c
IQR (25th percentile to 75th percentile).
d
PVN resolution for only subjects with negative plasma PCR readings during follow-up were on the basis of negative BK viremia by PCR during follow-up; data are available from n=116 subjects.